NASDAQ$ABCL
AbCellera Biologics Inc. · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported strong growth across key performance indicators related to the partnership business, including new programs under contract, program starts, and new molecules in the clinic.
AbCellera reported Q2 2021 financial results with a total revenue of $27.6 million, up from $11 million in Q2 2020. The company incurred a net loss of $2.3 million, compared to net earnings of $6.7 million in Q2 2020.
- Earned $27.6 million in total revenue, including $22.2 million in milestones and royalties.
- Incurred net loss of $2.3 million, compared to generating net earnings of $6.7 million in Q2 2020.
- Added 19 programs under contract with four new partners, resulting in a cumulative total of 138 programs under contract with 33 different partners.
- Confirmed three new molecules advanced into the clinic, bringing the cumulative total to four.
Headline financials
Revenue & EPS history
AbCellera · Revenue · Quarterly
$27.6M
Revenue by segment
AbCellera · $5.48M total across 2 segments · Q2 2021
- Research Fees$5.22M—95.2%
- Licensing and Royalty$263K—4.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.2%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+17.1%
Q2 2021
Best reaction
-13.9%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | -21.8% | -2.9% | |
| Q4 2025 | -1.5% | +18.6% | +1.6% | |
| Q3 2025 | -13.9% | -12.4% | -21.4% | |
| Q1 2025 | +1.0% | +2.0% | +21.4% | |
| Q4 2024 | -11.3% | -18.2% | -20.9% | |
| Q3 2024 | -0.4% | -1.1% | +6.2% | |
| Q2 2024 | -4.7% | -2.9% | -12.0% | |
| Q1 2024 | -6.6% | -6.8% | -8.0% | |
| Q4 2023 | -9.9% | -8.8% | -11.8% | |
| Q3 2023 | +14.1% | +6.8% | +17.2% | |
| Q2 2023 | -13.0% | -15.1% | -19.5% | |
| Q1 2023 | -9.1% | -14.1% | +3.0% | |
| Q4 2022 | -8.3% | -12.7% | -23.8% | |
| Q3 2022 | -1.7% | +13.1% | -7.2% | |
| Q2 2022 | +13.4% | +16.3% | -3.9% | |
| Q1 2022 | -12.0% | +11.2% | +29.1% | |
| Q4 2019 | +8.1% | +9.4% | +15.5% | |
| Q4 2021 | +8.1% | +9.4% | +15.5% | |
| Q3 2020 | -7.8% | -2.0% | -5.1% | |
| Q2 2018 | +16.3% | +10.3% | +25.0% | |
| Q2 2021 | +17.1% | +8.6% | +24.3% | |
| Q1 2018 | +0.1% | -5.2% | -24.1% | |
| Q1 2021 | +3.4% | +7.4% | -15.7% | |
| Q4 2018 | +7.8% | +24.1% | +21.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro